- Open Access
A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1
Molecular Cancer volume 18, Article number: 131 (2019)
The Correction to this article has been published in Molecular Cancer 2019 18:149
The RTK/PI3K/AKT pathway plays key roles in the development and progression of many cancers, including GBM. As a regulatory molecule and a potential drug target, the oncogenic role of AKT has been substantially studied. Three isoforms of AKT have been identified, including AKT1, AKT2 and AKT3, but their individual functions in GBM remain controversial. Moreover, it is not known if there are more AKT alternative splicing variants.
High-throughput RNA sequencing and quantitative reverse transcription-PCR were used to identify the differentially expressed circRNAs in GBM samples and in paired normal tissues. High throughput RNA sequencing was used to identify circ-AKT3 regulated signaling pathways. Mass spectrometry, western blotting and immunofluorescence staining analyses were used to validate AKT3-174aa expression. The tumor suppressive role of AKT3-174aa was validated in vitro and in vivo. The competing interaction between AKT3-174aa and p-PDK1 was investigated by mass spectrometry and immunoprecipitation analyses.
Circ-AKT3 is a previously uncharacterized AKT transcript variant. Circ-AKT3 is expressed at low levels in GBM tissues compared with the expression in paired adjacent normal brain tissues. Circ-AKT3 encodes a 174 amino acid (aa) novel protein, which we named AKT3-174aa, by utilizing overlapping start-stop codons. AKT3-174aa overexpression decreased the cell proliferation, radiation resistance and in vivo tumorigenicity of GBM cells, while the knockdown of circ-AKT3 enhanced the malignant phenotypes of astrocytoma cells. AKT3-174aa competitively interacts with phosphorylated PDK1, reduces AKT-thr308 phosphorylation, and plays a negative regulatory role in modulating the PI3K/AKT signal intensity.
Our data indicate that the impaired circRNA expression of the AKT3 gene contributes to GBM tumorigenesis, and our data corroborate the hypothesis that restoring AKT3-174aa while inhibiting activated AKT may provide more benefits for certain GBM patients.
GBM is one of the most lethal human cancers. With multimodal treatments available, including surgery, radiation and chemotherapy, the median survival time of patients with GBM is only 12–14 months . Although many novel strategies have been tested for years, no effective target therapy has been validated in GBM to function better than temozolomide [1, 2]. The disruption of RTK/PI3K signaling is considered to be one of the major pathways during GBM tumorigenesis and progression . The aberrant activation of RTK/PI3K signaling in GBM has multiple causes: the frequent amplification/mutation of EGFR (~ 45%), the mutation/homozygous deletion of PTEN (~ 36%) and the mutation of PI3K (~ 15%); these mutations collaboratively activate this pathway in ~ 88% GBM patients . AKT, a serine-threonine kinase, is a key downstream effector of the RTK/PI3K pathway. Activated AKT, which is observed in ~ 70% GBM patients, especially in those with PTEN loss , mediates tumor cells proliferation, survival and malignant transformation through multiple downstream targets, including GSK-3, MDM2, and mTOR et al. . The above evidence suggests that AKT is a reasonable therapeutic target for some GBM patients.
The human AKT family has three isoforms, AKT1, AKT2 and AKT3. Although they share with very similar sequences, isoform-specific functions have been reported. In knockout mice, AKT1 deprivation showed a growth retardation phenotype, and mice with AKT2 deletion had type II diabetes [7, 8]. In contrast, AKT3 facilitated postnatal brain development instead of homeostasis, indicating the critical role of AKT3 in the central nervous system . AKT3, but not AKT1 or AKT2, was required for the anchorage-independent growth of transformed astrocytes and human glioma cells . Although AKT3 expression was reported to be downregulated in GBM, it has shown a stronger kinase activity than that of AKT2 . However, AKT3 was also shown to delay GBM progression in some GBM cases, raising the controversial role of AKT3 in GBM tumorigenesis .
We have previously reported that circular RNA encodes functional peptides or proteins in GBM [13,14,15]. By using high-throughput RNA sequencing from GBM clinical samples and paired normal brain tissues, we identified that circ-AKT3 has low expression levels in GBM. Circ-AKT3 encodes a 174 amino acid novel protein, which we named AKT3-174aa. Functionally inverse to AKT3, AKT3-174aa blocks AKT thr-308 phosphorylation by competing with activated PDK1 and inhibits the proliferation, radiation resistance and tumorigenicity of GBM cells. Our results show that circ-AKT3 is a novel functional AKT transcript variant and that in addition to PTEN, AKT-174aa is a newly identified negative regulator of the RTK/PI3K pathway.
Human cancer and normal tissues
All GBM (n = 38 and their paired, peripheral normal brain tissues) samples were collected from the Department of Neurosurgery at the 1st Affiliated Hospital of Sun Yat-sen University. The human materials were obtained with informed consent, and the study was approved by the Clinical Research Ethics Committee.
Animal care and ethics statement
Four-week-old female BALB/c-nu mice were purchased from the Laboratory Animal Center of Sun Yat-sen University. The mice were housed in a temperature-controlled (22 °C) and light-controlled pathogen-free animal facility with free access to food and water. All experimental protocols concerning the handling of mice were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University.
Cell culture and RNase R treatments
All cells used in this study were tested for mycoplasma contamination and were authenticated by STR sequencing. The 293 T cell line was purchased from ATCC (ATCC number: CRL-11268), and the U373 cell line was also from ATCC (ATCC number: CRL-1620). The U251, HS683, and SW1783 cell lines were kindly provided by Dr. Suyun Huang, VCU. These cells were cultured in Dulbecco’s modified Eagle’s medium (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GIBCO BRL, Grand Island, NY, USA) according to standard protocols. GICs were kindly provided by Dr. Jeremy Rich, UCSD. These cells were cultured in DMEM/F12 medium supplemented with B27 supplement (Life Technologies), bFGF and EGF (20 ng/ml each). iPS derived neural stem cells were kindly provided by Dr. Peng Xiang, SYSU. These cells were culture with StemPro® NSC SFM (Cat. no. A10509–01) supplemented with 2 mM GlutaMAX™-I Supplement (Cat. no. 35050), 6 U/mL heparin (Sigma, Cat. no. H3149), and 200 μM ascorbic acid (Sigma, Cat. no. A8960). NHA were purchased from Lonza and were cultured using an AGMTM Astrocyte Growth Medium Bullet Kit™ (Lonza, Walkersville, MD, USA) as recommended by the manufacturer. RNase R (Epicenter Biotechnologies, Madison, WI, USA) treatment (20 U/μl) was performed on total RNA (20 μg) at 37 °C for 15 min.
Total RNA was extracted using Trizol reagent kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. RNA quality was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and checked using RNase free agarose gel electrophoresis. After total RNA was extracted, eukaryotic mRNA was enriched by Oligo(dT) beads, while prokaryotic mRNA was enriched by removing rRNA by Ribo-ZeroTM Magnetic Kit (Epicentre, Madison, WI, USA). Then the enriched mRNA was fragmented into short fragments using fragmentation buffer and reversely transcripted into cDNA with random primers. Second-strand cDNA were synthesized by DNA polymerase I, RNase H, dNTP and buffer. Then the cDNA fragments were purified with QiaQuick PCR extraction kit (Qiagen, Venlo, The Netherlands), end repaired, poly(A) added, and ligated to Illumina sequencing adapters. The ligation products were size selected by agarose gel electrophoresis, PCR amplified, and sequenced using Illumina HiSeq2500 by Gene Denovo Biotechnology Co. (Guangzhou, China).
Data was mapped to reference genome by TopHat2 (version 2.1.1), then transcripts abundances were quantified by software RSEM (version 1.2.19). Firstly, a set of reference transcript sequences were generated and preprocessed according to transcripts (in FASTA format) and gene annotation files (in GTF format). Secondly, reads were realigned to the reference transcripts by Bowtie alignment program and the resulting alignments were used to estimate transcript abundances. The transcript expression level was normalized by using FPKM (Fragments Per Kilobase of transcript per Million mapped reads). Value of transcripts from the same gene were merged to obtain reads counts and expression level at gene level. Differentially expressed genes (DEGs) were also identified by the edgeR package (version 3.12.1) (http://www.r-project.org/) with general linear model and a threshold of fold change > 2 and FDR < 0.05. KEGG pathway enrichment analysis (Fisher’s Exact Test) was performed for DEGs.
Antibodies against pan-AKT (#4691, 1:1000), phospho-AKT Thr308 (#13038, 1:1000), phospho-AKT Ser473 (#4060, 1:1000), AKT1 (#2938, 1:1000), AKT2 (#3063, 1:1000), AKT3 (#14982, 1:1000), PDK1 (#13037, 1:1000) and p-PDK1 (#3438, 1:1000) were from Cell Signaling Technology (Danvers, MA, USA). Antibodies against γ- H2AX (ab2893; 1:1000), PTEN (ab32199; 1:10000), EGFR (ab32430; 1:5000) were from Abcam (Cambridge, MA, USA). Antibodies against flag (F1804, 1 mg/mL; 1:1000) and beta-tubulin (T5201; 1:5000) were from Sigma-Aldrich (St. Louis, MO, USA).
Statistical tests were conducted using GraphPad Prism (Version 8; La Jolla, CA, USA) software unless otherwise indicated. The data are presented as the mean ± s.e.m. from three independent experiments. For the parametric data, unpaired, two-tailed Student’s t-tests were used. For nonparametric data, the two-sided Mann–Whitney test was used. Data distribution was assumed to be normal, but this was not formally tested. A level of P < 0.05 was used as the cutoff for significant differences. For all experiments, analyses were done in biological triplicates. No animals or data points were excluded from the analyses for any reason. Blinding and randomization were performed in all experiments. Statistical analyses for the RNA-seq data are described above in the respective sections.
Circ-AKT3 has low expression levels in GBM samples/cell lines compared with its expression in normal brain tissues/normal human astrocytes (NHA) and neural stem cells
We previously generated a circRNA profiling database using the RNA-seq data of ribosomal RNA-depleted total RNA from clinical GBM tissues and paired adjacent normal tissues . The RNA from ten GBM samples was combined for the tumor group, and the RNA from their periphery normal tissues was combined as the normal group. Both tumor group and normal group were sequenced on an Illumina HiSeq™ 2500 with RNase R enrichment. The reads obtained were mapped to reference ribosomal RNA sequences (Bowtie2, http://bowtie-bio.sourceforge.net/bowtie2/) and to a reference genome (TopHat2, http://ccb.jhu.edu/software/tophat/) [16, 17]; 20-mers from both ends of the unmapped reads were extracted and aligned to the reference genome to find unique anchor positions within the splice site. Anchor reads that aligned in the reverse orientation (head-to-tail) indicated circRNA splicing and were then subjected to find_circ (https://omictools.com/find-circ-tool) to identify the circRNAs . A candidate circRNA was called if it was supported by at least two unique back-spliced reads in one sample. A total of 31,145 circRNAs were identified by this approach (PRJNA355185 (SRP095744)), 6442 of which were matched in circBase (http://www.circbase.org/) . By analyzing the most differentially expressed circRNAs between tumor group and normal group, we identified circ-AKT3 (Fig. 1a, upper panel). There are three circular RNAs generated from the AKT3 gene (hsa_circ_0017250, hsa_circ_0112784 and hsa_circ_0112781) that were detected in our RNA-seq data, and all of them had a lower expression in GBM compared with that in normal tissues (Fig. 1a, lower panel). Another circRNA generated from AKT3 (hsa_circ_0000199) was recently reported to be upregulated in gastric cancer . We did not find it in our RNA-seq data, which could be explained by organ-specificity. Of these three circRNAs, hsa_circ_0017250 and hsa_circ_0112781 were more abundantly expressed in normal brain tissues. Moreover, only hsa_circ_0017250 contains a complete ORF as shown in Fig. 1b. Due to the significant lower level of hsa_circ_0017250 (termed as circ-AKT3) in tumor group compare with that in normal group (11 folds), we next explored its endogenous expression.
Circ-AKT3 is generated from exon 3 to exon 7 of the AKT3 gene with a full length of 524 nt. Divergent primers spanning the circ-AKT3 junction amplified the predicted PCR products, and Sanger sequencing confirmed the circular junction (Fig. 1c). Compared with linear form of AKT3 mRNA, circ-AKT3 is resistant to RNase R digestion  and has a longer half-life (Fig. 1d). We designed a circ-AKT3 overexpression plasmid and two circ-AKT3 junction shRNAs (Fig. 1e, upper panel). These plasmids or shRNAs could specifically upregulate or knockdown the circ-AKT3 level in 293 T cells, without affecting the linear AKT3 mRNA (Fig. 1e, lower panel). Immunofluorescence was performed using a junction-specific probe and showed that circ-AKT3 mostly localized in the cytoplasm of NHA cells and that the overexpression or knockdown of circ-AKT3 could enhance or attenuate the fluorescence signal, suggested the specificity of the probes (Fig. 1f, left panel). Cell fraction qPCR using circ-AKT3 or linear circ-AKT3-specific primers further confirmed the cytoplasmic localization of this circRNA. Moreover, compare with random primers reversely transcript cDNA, oligo dT reversely transcript cDNA could not amplify circ-AKT3 (Fig. 1f, right panel). Northern blot analysis verified the ~ 524 nt band of endogenous circ-AKT3 in NSC and NHA cells, which could be enhanced or attenuated by the overexpression or stable knockdown of circ-AKT3, respectively, by the indicated constructions (Fig. 1g). By using junction-specific primers, we explored circ-AKT3 expression patterns in several established GBM cell lines, glioblastoma-initiating cells (GICs) and a cohort of 38 GBM patient tissues as we previously reported . Compared with those in NSC and NHA cells, GBM cells and GICs expressed lower levels of circ-AKT3. In clinical samples, circ-AKT3 expression was also low in GBM samples compared with that in normal brain tissues (Fig. 1h, left). We also found that linear AKT3 mRNA had a lower expression in GBM cells or clinical samples than the expression in normal brain tissues by using AKT3 mRNA-specific primers (Figs. 1h, right) as previously reported . We did not find that the circ-AKT3 expression had a significant correlation with the GBM molecular subtypes or the IDH1 status (Fig. 1i).
Circ-AKT3 encodes a 174 amino acid (aa) novel protein, AKT3-174aa
Circ-AKT3 has a predicted ORF, which may encode a 174 aa protein by using an overlapping start-stop codon ‘UAAUGA’ (Fig. 2a). We verified the activity of the predicted IRES in circ-AKT3 by using a dual-luciferase assay, as shown in Fig. 2b. Driven by this IRES, the 174 aa product covers the same sequences as AKT3 from amino acids 62–232, with a special C-terminal of ‘Ans Ala Ser’. We used an antibody against the middle part of AKT3, which should recognize both AKT3 and AKT3-174aa (Fig. 2c). We found that in established cell lines and paired clinical GBM samples, AKT3-174aa was lowly expressed in cancerous cells/tissues compared with that in normal cells/tissues (Fig. 2d and Additional file 2: Figure S1). To confirm that the 174 aa predicted protein was encoded by circ-AKT3, we used the circ-AKT3 overexpression plasmid, described in Fig. 1, and a linearized AKT3-174aa overexpression plasmid. In U251 cells, which has lower endogenous circ-AKT3 levels, the transfection circ-AKT3 and the linearized AKT-174aa plasmid both resulted in the predicted AKT-174aa band, while the overexpression circ-AKT3 IRES-Mut plasmid did not (Fig. 2e). Mass spectrometry followed by SDS-PAGE using circ-AKT3 overexpression U251 cells further confirmed the AKT3-174aa peptide sequences in the predicted molecular weight (Fig. 2f). In contrast, two junction-specific shRNAs targeting circ-AKT3 could reduce AKT3-174aa expression in NHA cells, which have high endogenous levels of circ-AKT3, without affecting the linear AKT3 mRNA (Fig. 2g). These results prove that circ-AKT3 encoded this 174 aa novel protein, which we termed AKT3-174aa. Immunofluorescence using an anti-flag antibody confirmed the cytoplasmic localization of AKT3-174aa-Flag in U251 cells, as shown in Fig. 2h. In clinical samples, AKT3-174aa expression negatively correlated with GBM patient prognosis (the cohort of 38 GBM patients, determined by semiquantitative immunoblotting as we previously described ); this suggests that AKT3-174aa may be a prognostic marker for GBM patients (Fig. 2i). In contrast, the linear AKT3 expression levels did not have a correlation with the overall survival of GBM patients in this study cohort or in the TCGA database (Fig. 2j).
AKT3-174aa as a tumor suppressor that inhibits the GBM malignant phenotype
To explore the biological functions, we established two AKT3-174aa overexpression cell lines and two AKT3-174aa stable knockdown cells, according their endogenous circ-AKT3 expression level, by using a circ-AKT3 overexpression plasmid, a linearized AKT3-174aa plasmid or a circ-AKT3 junction shRNA expression plasmid. The IRES-mutated circ-AKT3 and the scrambled shRNA were used as negative controls (Additional file 2: Figure S2). Overexpressed circ-AKT3 or linearized AKT3-174aa, but not IRES-mutated circ-AKT3, elevated the AKT3-174aa level in U251 and U373 cells without affecting the AKT1, AKT2 or AKT3 expression. The stable knockdown of circ-AKT3 in SW1783 cells and in Hs683 anaplastic glioma cells only reduced AKT3-174aa expression, instead of reducing that of AKT1, AKT2 and AKT3 (Fig. 3a). The overexpression of circ-AKT3, but not of IRES-mutated circ-AKT3, inhibited cell proliferation in both U251 and U373 cells, while knocking down circ-AKT3 promoted SW1783 and Hs683 cell growth (Fig. 3b). The AKT3-174aa expression level negatively regulated plate colony formation and anchorage-independent growth (Fig. 3c). Additionally, AKT3-174aa expression enhanced the GBM cell sensitivity to radiation while AKT3-174aa knockdown strengthened the insensitivity of anaplastic astrocytoma cells to IR, supporting the tumor-suppressive role of AKT3-174aa (Fig. 3d).
AKT3-174aa, but not circ-AKT3, exerts the biological functions
Although the IRES-mutated circ-AKT3 plasmid could not translate AKT3-174aa in vivo, the mutated circRNA structure may affect its potential functions. To further exclude the possibility that circ-AKT3, but not AKT3-174aa, induced the above functions, we restored AKT3-174aa expression in SW1783 and Hs683 cells with the stable knockdown of circ-AKT3 by using an AKT3-174aa linearized plasmid (Fig. 4a). AKT3-174aa re-expression reversed the malignant phenotypes induced by the stable knockdown of circ-AKT3 (Fig. 4b-d). In contrast, the overexpression circ-AKT3 ATG-mutated plasmid (mutated at the start codon of circ-AKT3), which merely alter circ-AKT3 expression and structure, could not inhibit the malignant phenotype of the U251 and U373 cells, including cell proliferation, plate and anchorage-independent colony formation, and IR resistance (Fig. 4e-h). The above results prove that AKT3-174aa, but not circ-AKT3, exerted a tumor-suppressive role in GBM.
AKT3-174aa inhibits the phosphorylation of AKT Thr308
To investigate the molecular mechanism that AKT3-174aa involved in, we conducted RNA-seq analysis of U251 and U373 cells that were stably expressing circ-AKT3 or circ-AKT3 IRES-mut plasmid. A total of 1873 and 2471 Differentially expressed genes (DEGs) were detected for U251 and U373, respectively (Additional file 2: Figure S3 and S4, Additional file 3: Table S1 and Additional file 4: Table S2). Both DEGs and KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis displayed a notable association with cancer-relation pathways, including PI3K-Akt signaling pathway, TNF signaling pathway, MAPK signaling pathway et al. (Fig. 5a).
As AKT3-174aa shared same sequences as AKT3, we first checked the activation of AKT isoforms in AKT3-174aa overexpression or knockdown cells. AKT3-174aa did not affect the total AKT1, AKT2 or AKT3 mRNA or protein expression level (Fig. 5b). Instead, AKT3-174aa inhibited AKT-thr308 but did not inhibit AKT-ser473 or the phosphorylation of U251, U373, SW1783 and Hs683 cells (Fig. 5b). In human GBM, AKT activation is often associated with PTEN alternation, such as the mutation/loss of heterozygosity or the increase in EGFR mutation/amplification . In AKT3-174aa overexpressed U251 and U373 cells and in AKT-174aa stable knockdown SW1783 and Hs683 cells, we did not find a change in p-EGFR (thr1068). In PTEN wild-type SW1783 and Hs683 cells, PTEN expression was also not affected after AKT3-174aa knockdown (Fig. 5b). Together with the fact that AKT3-174aa attenuated p-AKT-thr308 in PTEN-deficient U251 and U373 cells, we implied that AKT3-174aa exerted its function independently from PTEN or EGFR. AKT3 was reported to have a low expression in GBM tissues but exhibited higher kinase activity than that in the control tissues . To explore whether AKT3-174aa had AKT isoform-specific functions, we used U251 cells with AKT3-174aa overexpression to perform the AKT-isoform specific immunoprecipitation (IP). The overexpression of AKT3-174aa reduced both the AKT2 and AKT3 thr-308 phosphorylation but not the ser-473 phosphorylation, indicating that AKT3-174aa affected more than AKT3. AKT1 phosphorylation was neglectable in U251 cells, as was reported previously . Similar results were acquired in SW1783 cells with the stable knockdown of circ-AKT3 (Fig. 5c). Taking these information together, we showed that AKT3-174aa exerted its effects upstream of p-AKT instead of affecting the AKT isoforms themselves.
AKT activation required several steps as follows: the PH domain is first recruited by activated PI3K, which is located on the cell membrane, to expose the thr-308 site . Next, activated PDK1 phosphorylated thr-308 of AKT , and finally, mTOR sequentially phosphorylated the ser-473 site to fully activate AKT . Although PDK1 or p-PDK1 expression was not affected by AKT3-174aa, we found that p-PDK1 was a potential interacting protein in the Flag-AKT3-174aa immunoprecipitation complex by using mass spectrometry (MS), as shown in Fig. 5d. In 293 T cells, Flag-tagged AKT3-174aa could mutually interact with p-PDK1, suggesting the interaction of AKT3-174aa and p-PDK1 in vivo (Fig. 5e). Although purified GST-tagged AKT3-174aa could not pull-down His-tagged PDK1, the in vitro IP by incubation of eukaryotic-purified His-PDK1 with prokaryotic-purified GST-AKT3-174aa could induce their mutual interaction, and this further confirmed that AKT3-174aa interacted with activated PDK1 (Fig. 5f). Immunofluorescence staining in U251 cells transfected with Flag-tagged AKT3-174aa also supported the colocalization of AKT3-174aa with p-PDK1, suggesting that AKT3-174aa preferred to inhibit thr-308 of AKT via interacting with p-PDK1 (Fig. 5g).
AKT3-174aa is a natural dominant-negative variant of AKT
Because AKT3-174aa shares the same sequences with AKT3 from amino acids 62–232, we inferred that AKT3-174aa may compete with AKT isoforms to bind to p-PDK1. We showed that the p-PDK1 activity was inhibited after AKT3-174aa overexpression (Fig. 6a). Additionally, AKT kinase activity was inhibited in U251 and U373 AKT3-174aa overexpressed cells, while this activity was enhanced in SW1783 and Hs683 AKT3-174aa stable knockdown cells (Fig. 6b). Furthermore, other p-PDK1 downstream effectors, such as p-SGK , were also inhibited significantly by AKT3-174aa (Fig. 6b). Next, we dose-dependently transfected circ-AKT3 into U251 cells and performed immunoprecipitation with AKT2, AKT3 and p-PDK1. With the increased expression of AKT3-174aa, p-AKT-thr308 decreased in both the AKT2 and AKT3 IPs (Fig. 6c). In SW1783 cells with a dose-dependent transfection of circ-AKT3 siRNA, AKT3-174aa deprivation enhanced the p-PDK1 and AKT2/3 interaction and AKT-thr308 phosphorylation (Fig. 6d). Specifically, p-PDK1 pull-down increased the level of AKT3-174aa but decreased the levels of AKT2 and AKT3 in U251 cells; this is in contrast to the effects in SW1783 cells, where we showed that AKT3-174aa is a protein decoy that limited the aberrant activation of p-AKT through dominant-negative regulation (Fig. 6c and d).
AKT3-174aa suppresses GBM tumorigenicity in vivo
Next, we tested the tumor-suppressive role of AKT3-174aa in mice intracanal tumor models. Nude mice were intracranially injected with AKT3-174aa overexpressed (circular or linearized, respectively) U251 and U373 cells. AKT3-174aa overexpression significantly increased the total survival time of the mouse models, as indicated in Fig. 7a. Conversely, knocking down AKT3-174aa promoted the tumor formation of SW1783 and Hs683 cells in vivo, and the wild-type SW1783 and Hs683 cells could not do the same (Fig. 7b). In mice xenograft tumors, AKT3-174aa overexpression negatively correlated with the expression levels of p-AKT-thr308; this supported the hypothesis that AKT3-174aa inhibits the AKT activation-induced malignant phenotype (Fig. 7a, b). Together, our results show that AKT3-174aa is a critical negative regulator of PI3K/AKT signaling during GBM tumorigenesis (Fig. 7c).
Of the multiple oncogenic signaling pathways that drive GBM tumorigenesis and progression, the RTK/PI3K/AKT pathway plays a central role. Evidence has shown that at least one RTK status was found altered in 67% of GBM cases overall, including EGFR, PDGFRA, MET and FGFR2/3. Meanwhile, the PI3K mutation was found in 25% of GBM cases. Although the PI3K and PTEN mutations were mutually exclusive, 59% of GBM cases showed one or the other. After adding up these genetic alterations, nearly 90% of GBM cases had at least one alteration in RTK/PI3K/AKT signaling and 39% had two or more [3, 27]. AKT represents a nodal point in this pathway. After PI3K activation, AKT was recruited to the plasma through the PH-domain and was them phosphorylated sequentially at thr308 and ser473 to become fully activated [28, 29]. Specifically, PDK1 (another PH domain-containing kinase) directly phosphorylated AKT at thr308, which is the most critical initial step for AKT activation . AKT activation promoted cancer progression through the following three major biological functions: survival, proliferation and growth . So far, three AKT isoforms have been identified (AKT1, AKT 2 and AKT3), which, in general, are broadly expressed, although there are some isoform-specific features. In breast cancer, AKT1 had been demonstrated to suppress while AKT2 promotes migration and invasion [32, 33]. In PTEN-deficient prostate cancer, AKT2, but not AKT1, mediates cellular survival and proliferation . AKT3, but not AKT1 or AKT2, mediated the resistance to apoptosis in BRAF-targeted melanoma cells; promoted anchorage-independent growth in triple negative breast cancer; and controlled the VEGF-induced angiogenesis in ovarian cancer [34,35,36]. However, the functions of AKT3 in GBM remain controversial: although reports have shown that AKT3 had lower expression levels, its kinase activity was higher than that of AKT2 . Additionally, AKT3 was reported to exert a tumor suppressive function in GBM . In current study, we showed that AKT3 was downregulated in GBM compare with normal brain tissue, which was consistent with the results of previous studies. But the consequences of the AKT3 downregulation in GBM may not be only due to its higher kinase activity; as AKT3-174aa may also play its part.
We and other groups have shown that circRNAs could encode functional peptides or proteins [13, 14, 37, 38]. Compared with their linear host gene products, circRNA encoded proteins or peptides are usually exerted independently of the biological functions. For example, we found that circPINTexon2 encoded PINT87aa, which is involved in translation elongation, while LINC-PINT showed a functional dependence with PRC2 [14, 39]. The most recent study also supported that circRNAs and linear mRNAs may have individual functions during prostate cancer carcinogenesis . On the other hand, some translational products of the circRNAs involved in their host gene functions, such as SHPRH-146aa protects SHPRH from degradation  and FBXW7-185aa induce c-Myc degradation . Interestingly, two recent reports have shown that AKT hyperactivation required SETDB1-induced methylation during tumorigenesis [41, 42]. The reported K64, K140 and K142 methylation sites were all located inside AKT3-174aa, implying that AKT3-174aa also may protect AKT from being methylated; however, further evidence is needed. The potential multiple ‘safe-guard’ role of AKT3-174aa showed that it may be a critical negative regulator of PI3K/AKT signaling expect for PTEN. Vo et al. recently reported that although circRNAs were globally expressed in cancers at low levels, circ-AKT3 seemed to be one of the exclusions . However, their study did not include GBM samples, which were reported to have lower linear AKT3 levels compare with those of the other malignancies including breast cancer, ovarian cancer and melanoma [11, 34,35,36, 44].
Except for inducing glioma invasion and anchorage-independent growth, AKT3 was reported to significantly activate DNA repair and resistance to radiation and chemotherapy in GBM cases . However, AKT3 did not show any prognostic correlations with GBM patients in the TCGA database. We inferred that the lower expression of AKT3 in some GBM cases may confound the oncogenic characters of AKT3 and may induce the nonsignificant prognostic results. Instead, AKT3-174aa expression showed as a positive correlation with the patients’ total survival with GBM in our study. Considering that AKT3-174aa is one of the few negative regulators of PI3K/AKT signaling (others include PTEN, PHLPP , and CTMP ), its expression level should be more intensively tested in larger cohort to confirm whether it is an independent biomarker for GBM or other types of human cancers.
Given the central role of PI3K/AKT signaling in GBM, targeting PI3K or AKT is a logical rationale in developing novel therapeutic strategies. However, PI3K inhibitors, such as LY294002/wortmannin, and AKT inhibitors, such as perifosine, were only applied in experimental studies instead of in clinical trials. Basically, the unsatisfactory results of these novel drugs were attributed to the difficulties to penetrate the blood brain barrier and the fast restoration of p-AKT . Although the tumor-suppressive role of AKT3-174aa prevents its druggable potential, we think that the low expression of AKT3-174aa may allow for AKT be easily exposed to p-PDK1 or SETDB1 in GBM, and this makes AKT more sensitive to activation cascades. Thus, effectively restore AKT3-174aa expression may benefit certain GBM patients to PI3K/Akt signaling target therapy, although the optimized delivery system for BBB penetration is required. Our results provide some evidence that the internal balance of the abovementioned genes’ alternative splicing products needs to be restored during GBM target-therapy, which could enhance or maintain the drug efficiency.
Circ-AKT3 is a newly identified AKT3 transcriptional variant. Circ-AKT3 encodes AKT3-174aa, which interacts with p-PDK1 as a molecular decoy. Circ-AKT3 and AKT3-174aa are expressed at low levels in GBM, which could more easily induce AKT-thr308 phosphorylation and sequential activation by p-PDK1. Restoring the expression of AKT3-174aa inhibits the cells proliferation, survival and tumorigenicity of GBM in vitro and in vivo. As a novel negative regulator of PI3K/AKT signaling, AKT3-174aa is a potential prognostic marker for GBM patients and may have future potential clinical uses.
Availability of data and materials
Raw sequencing and processed RNA Seq data from this study have been deposited into NCBI SRA: SRP095744 and SRP216548.
Epidermal growth factor receptor
Internal ribosomal entry site
Open reading frame
Phosphate and tension homology deleted on chromosome ten
Receptor tyrosine kinase
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Knisely JP, Baehring JM. A silver lining on the horizon for glioblastoma. Lancet Oncol. 2009;10:434–5.
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.
Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.
Chin YR, Yuan X, Balk SP, Toker A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014;4:942–55.
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16:100.
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001;15:2203–8.
Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292:1728–31.
Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J, Hemmings BA. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005;132:2943–54.
Endersby R, Zhu X, Hay N, Ellison DW, Baker SJ. Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res. 2011;71:4106–16.
Mure H, Matsuzaki K, Kitazato KT, Mizobuchi Y, Kuwayama K, Kageji T, Nagahiro S. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro-Oncology. 2010;12:221–32.
Joy A, Kapoor M, Georges J, Butler L, Chang Y, Li C, Crouch A, Smirnov I, Nakada M, Hepler J, et al. The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. J Neuro-Oncol. 2016;130:43–52.
Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, Huang N, Yang X, Zhao K, Zhou H, et al. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis. J Natl Cancer Inst. 2018;110:304–15.
Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, Chen W, Gao X, Zhao K, Zhou H, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37:1805–14.
Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, Liu H, Xu J, Xiao F, Zhou H, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018;9:4475.
Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nat Methods. 2012;9:357–9.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
Glazar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. RNA. 2014;20:1666–70.
Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, Xu Z, Zeng A, Zhang X, Zhang X, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18:71.
Suzuki H, Zuo Y, Wang J, Zhang MQ, Malhotra A, Mayeda A. Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res. 2006;34:e63.
Chautard E, Ouedraogo ZG, Biau J, Verrelle P. Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness. J Neuro-Oncol. 2014;117:205–15.
Isakoff SJ, Cardozo T, Andreev J, Li Z, Ferguson KM, Abagyan R, Lemmon MA, Aronheim A, Skolnik EY. Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J. 1998;17:5374–87.
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261–9.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.
Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J. 1999;18:3024–33.
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550–63.
Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997;272:31515–24.
Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene. 1998;17:313–25.
Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 1997;277:567–70.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005;171:1023–34.
Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, Bissell MJ. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A. 2006;103:4134–9.
Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010;70:6670–81.
Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res. 2014;74:964–73.
Liby TA, Spyropoulos P, Buff Lindner H, Eldridge J, Beeson C, Hsu T, Muise-Helmericks RC. Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. Int J Cancer. 2012;130:532–43.
Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, Hanan M, Wyler E, Perez-Hernandez D, Ramberger E, et al. Translation of CircRNAs. Mol Cell. 2017;66:9–21.e27.
Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade M, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in Myogenesis. Mol Cell. 2017;66:22–37.e9.
Marin-Bejar O, Mas AM, Gonzalez J, Martinez D, Athie A, Morales X, Galduroz M, Raimondi I, Grossi E, Guo S, et al. The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element. Genome Biol. 2017;18:202.
Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, et al. Widespread and functional RNA circularization in localized prostate Cancer. Cell. 2019;176:831–843.e822.
Guo J, Dai X, Laurent B, Zheng N, Gan W, Zhang J, Guo A, Yuan M, Liu P, Asara JM, et al. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019;21:226–37.
Wang G, Long J, Gao Y, Zhang W, Han F, Xu C, Sun L, Yang SC, Lan J, Hou Z, et al. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol. 2019;21:214–25.
Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, et al. The landscape of circular RNA in Cancer. Cell. 2019;176:869–881.e813.
Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2:1093–103.
Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, et al. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A. 2015;112:3421–6.
Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 2012;31:1264–74.
Knobbe CB, Reifenberger J, Blaschke B, Reifenberger G. Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst. 2004;96:483–6.
We thank Dr. Jeremy Rich, Dr. Peng Xiang and Dr. Suyun Huang for providing cell lines used in this study. The authors thank the patients, study investigators, and staff who participated in this study.
This work was supported in part by the National Natural Science Outstanding Youth Foundation of China (81822033 to N.Z.), the National Key Research and Development Program of China (2016YFA0503000 to N.Z.), the National Natural Science Foundation of China (81572477 and 81772683 to N.Z., 81602185 to N.H.), and Science and Technology Program Key project of Guangzhou (201704020068, 201903010093 and 201604020004).
Ethics approval and consent to participate
All patients consented to an institutional review board-approved protocol that allows comprehensive analysis of tumor samples (Ethics committee of Sun Yat-sen University). This study conforms to the Declaration of Helsinki.
Consent for publication
Written informed consent for publication was obtained from the patients. All authors have agreed to publish this manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Materials and Methods. (DOCX 34 kb)
Figure S1. A. In the same blot as Fig. 2d, expression of AKT1, AKT2 and AKT T308 level were detected in established cell lines. Loading control was showed in Fig. 2d. B. Left, in the same blot as Fig. 2d, expression of AKT1, AKT2 and AKT T308 level were detected in several GBM samples and paired adjacent normal tissues. C. Expression of AKT3, AKT3-174aa, AKT1, AKT2 and AKT T308 level were detected in several GBM samples and paired adjacent normal tissues. Figure S2. Left, Hs683, SW1783 cells were stably overexpressed with control shRNA and circ-AKT3 shRNA. Circ-AKT3 level was detected by PCR. Right, U251 and U373 cells were stably overexpressed with circ-AKT3 IRES mut plasmid, circ-AKT3 plasmid or AKT3-174aa ORF. Circ-AKT3 level was detected by PCR. Error bars represent three independent experiments, **, p < 0.01, ***, p < 0.001. Figure S3. A total of 1873 and 2471 Differentially expressed genes (DEGs) were detected for U251 and U373, respectively. Figure S4. The volcano plot(a) and Heatmap (b) of differential expression genes (Fold change > 2 and FDR < 0.05) from ribosomal RNAs depleted RNA-seq. (DOCX 616 kb)
KEGG pathway analysis of U251 and U373 cells with stable circ-AKT3 overexpression. (XLSX 108 kb)
Differentally changed genges of U251 and U373 cells with stable circ-AKT3 overexpression. (XLSX 10005 kb)
About this article
Cite this article
Xia, X., Li, X., Li, F. et al. A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Mol Cancer 18, 131 (2019) doi:10.1186/s12943-019-1056-5